Eryaspase (asparaginase) Medicine 10 December 2019 Extended indication Behandeling van pancreatic adenocarcinoma die gefaald hebben op eerstelijns therapie. Therapeutic value No estimate possible yet Total cost Registration phase Clinical trials Product Active substance Eryaspase (asparaginase) Domain Oncology and Hematology Reason of inclusion New medicine (specialité) Main indication Pancreatic cancer Extended indication Behandeling van pancreatic adenocarcinoma die gefaald hebben op eerstelijns therapie. Current proprietary name Already available biosimilars / generics Proprietary name Graspa Manufacturer ERYtech Portfolio holder Mechanism of action Enzyme Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Asparagine modulator Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP Unknown Submission date 2022 Expected Registration 2023 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Estimated Primary Completion Date November 2020 phase 3. Therapeutic value Current treatment options chemotherapie Therapeutic value No estimate possible yet This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration 1 times every 2 weeks Dosage per administration 100 U/kg References NCT03665441 Additional remarks Eryaspase (Asparaginase) wordt naast chemotherapie gegeven. Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References NKR Additional remarks In totaal zijn er 1.743 patiënten met stadium III en stadium IV alvleesklierkanker. Gezien de nieuwe behandelopties voor pancreascarcinoom is het nog onduidelijk hoeveel patiënten er in de tweedelijn zullen worden behandeld. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions No Indication extensions References AdisInsight Additional remarks Wel voor andere indicaties onderzocht (onder andere borstkanker), maar geen indicatie-uitbreidingen in de komende 2 jaar verwacht. Other information Additional remarks